UBS Downgrades Biogen (BIIB) to Neutral

March 22, 2019 3:57 AM

UBS downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $242.00 (from $395.00).

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $226.88 yesterday.

Categories

Analyst PT Change Downgrades

Next Articles